U.S. FDA Accepts Supplemental New Drug Application for Deucravacitinib (Sotyktu, Bristol Myers Squibb) in PsA
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib (Sotyktu, Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis.